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Abstract 
The human $29 ribosomal protein ($29 rp) cDNA has been isolated from differential hybridization screening of a colon carcinoma 
cDNA library. Northern blot analysis howed that the level of $29 rp mRNA was higher in undifferentiated HT29 human colon 
carcinoma cells than in a morphologically differentiated subclone under the same growth condition. Furthermore, the level of $29 rp 
mRNA was downregulated in rapidly proliferating HT29 cells, as compared to the contact inhibited cells. Interestingly, the amount of 
K rev-1 mRNA was inversely correlated with respect o the amount of $29 rp mRNA in these cells. To examine a functional link between 
$29 rp and Krev-I protein, we co-transfected the expression vectors containing wild-type or mutant $29 rp and mutationally activated 
K rev-l(63E) cDNAs into the v-Ki-ras-transformed NIH3T3 (DT) cells, and observed the induction of flat revertants. K rev-l(63E) 
induced acertain amount of flat colonies, while $29 rp alone also induced flat colonies at low frequencies. Interestingly, revertant-induc- 
ing activity of Krev-l(63E) was significantly enhanced by $29 rp. We have also demonstrated that a zinc finger-like domain of $29 rp 
indeed has a zinc binding activity and a derivative, $29 rp(ms), which was unable to bind zinc ion but still retained revertant inducing 
activity by itself, could not functionally interact with K rev-l(63E) protein. 
Keywords: $29 ribosomal protein; K rev-1; Tumor suppressor 
1. Introduction 
We have isolated a cDNA clone encoding human homo- 
logue of $29 rp from a colon carcinoma eDNA library. 
This small eDNA (0.3 kb) encodes a protein containing a 
zinc finger-like motif. In this report we show that the 
levels of $29 rp mRNA and K rev-1 mRNA were inversely 
correlated in HT29 colon carcinoma cell line under differ- 
ent growth conditions and at differentiation states. These 
findings suggest a functional ink between $29 rp and 
Krev-1 protein. Krev-1 mRNA encodes a Ras-related 
protein [1]. K rev-1 and the activated mutants induce flat 
revertants in DT cells at certain frequencies [2]. In this 
report, we demonstrate a novel functional interactions of 
$29 rp with Krev-1 protein in DT cells, conferred by a 
zinc finger-like motif of $29 rp. 
Abbreviations: $29 rp, $29 ribosomal protein; eDNA, complementary 
DNA; ORF, open reading frame 
* Corresponding author. Present address: Dept. of Biochemistry II, 
National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 
359, Japan. Fax: + 81 429 96-5190. 
a The sequence data of human and mouse $29 rps have been submitted 
to Genbank database under the accession numbers L31610 and L31609, 
respectively. 
2. Materials and methods 
2.1. Cell lines 
Human colon carcinoma cell line, HT29, was obtained 
from the American Type Culture Collection. The origin 
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and the method of maintenance of HT29 derivative, C III 
cells, and DT cells were described elsewhere [4,6]. 
rabbits. Peptide injection was repeated two to three times 
with Freund's adjuvant. 
2.2. Isolation of $29 rp cDNA 
The colon carcinoma-enriched subtraction cDNA li- 
brary constructed in pBluescript plasmid (SK-; Stratagene) 
has been described [3]. 32p-labeled total cDNA probes 
were generated from poly(A) RNA prepared from HT29 
and C III cells using superscript-RT (BRL). Differential 
hybridization was performed as described [4]. To isolate a 
larger cDNA fragment of $29 rp, h ZAP cDNA libraries 
constructed from SW620 human colon tumor cell line and 
BALB3T3 mouse fibroblasts were screened using 32p_ 
labeled $29 rp cDNA fragment. 
2.8. Reversion assay 
The original protocol for transfection assay for DT cells 
has been described [6]. 2 txg of pRc/CMV (with or 
without $29 rp cDNAs) and 4 ~g of pcEXV-I (with or 
without Krev-I cDNAs) were cotransfected into 105 DT 
cells. Transfectants were selected in medium containing 1 
mg/ml G418 (Sigma). Total drug-resistant colonies were 
counted on day 4 after replating, and flat colonies were 
counted on day 5. Frequency of reversion in DT cells (%) 
was scored. 
2.3. DNA sequencing 2.9. Zinc blot assay 
The cDNA cloned in pBluescript plasmid was se- 
quenced by the dideoxynucleotide chain termination 
method [5]. The sequencing reagents were obtained from 
U.S. Biochemical. 
2.4. Northern blot analysis 
Total RNAs (5 Ixg) extracted from cells were denatured 
and electrophoresed in 1.2% agarose gels containing 0.66 
M formaldehyde. Hybridization was performed as de- 
scribed [7] using cDNA probes labeled by the method of 
Feinberg and Vogelstein [8]. 
2.5. Site directed mutagenesis 
To make zinc finger disrupted mutant, $29 rp(ms), the 
283 bp fragment of the $29 rp cDNA was cloned into 
pBluescript plasmid and mutagenized using the oligo- 
nucleotide-directed in vitro mutagenesis system (Bio-Rad). 
The oligonucleotide 5'- GGTTCTCGCTCTGCTCGT- 
GTCGCTTCAAACCGGCACG-3' was used to mutate two 
cysteines (39C and 42C) into alanines. 
2.6. Expression vectors 
Full length cDNAs of wild-type $29 rp and 29 rp(ms) 
were constructed in a pET15a vector (Novagen). Bacteri- 
ally synthesized protein was purified and electrophoresed 
in a SDS polyacrylamide gel, then transferred to a nylon 
membrane (Immobilon; Millipore). Zinc binding assay us- 
ing 65ZNC12 was performed as described [9]. 
3. Results 
3.1. Isolation of a cDNA clone from colon carcinoma 
cDNA library 
In order to identify genes up-regulated in colon tumors, 
we have performed cDNA differential hybridization be- 
tween the sample of HT29 human colon carcinoma cells 
and the differentiated subclone, C III cells. HT29 cells 
form undifferentiated multilayers, whereas C III cells form 
differentiated columnar-epithelium-like monolayer in the 
confluent culture [10]. A cDNA clone, VF8, that hy- 
bridized preferentially with 32p-labeled cDNA from 
parental HT29 cells was isolated. 
The full length mutant K rev-l(63E) cDNA cloned in an 
eukaryotic expression vector, pcEXV-1, is described else- 
where [2]. Krev-l(63E) A cDNA was constructed by 
removing 195 bp BstXI fragment from the 5'-untranslated 
region of K rev-l(63E) cDNA. Full length wild-type $29 
rp and the zinc finger-disrupted mutant, $29 rp(ms), were 
cloned into an expression vector, pRc/CMV, containing 
neomycin resistant gene (Invitrogen). 
2. 7. Rabbit polyclonal antibody 
A synthetic peptide comprised of the 14 amino acid 
residues of $29 rp carboxy terminus was used to immunize 
3.2. Nucleotide sequence ofS29 rp cDNAs 
Nucleotide sequence of human VF8 shared 80% iden- 
tity with the mouse homologue which we have isolated 
from a mouse cDNA library. Human VF8 cDNA encodes 
three potential ORFs, however only one of them matched 
with a mouse ORF (Fig. 1). A database search revealed 
that the nucleotide sequence of human VF8 cDNA (283 
base) shares 72% identity with previously published rat 
$29 rp mRNA and the deduced sequence of VF8 consist- 
ing of 55 amino acids was identical to that protein [11]. 
From these results, we concluded that VF8 is a human 
homologue of $29 rp gene. 
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Fig. 2. A. Expression of Krec-1 and $29 rp genes. 5 I~g of total RNAs from HT29 (lane 1) and C III (lane 2) cells were analyzed by Northern blot 
hybridization. Two identical membranes were hybridized with human K ret,-1 cDNA and human $29 rp cDNA probes, respectively. A gel stained with 
ethidium bromide is shown on the bottom, kb, kilobases. B. Growth states of HT29 cells. A 106 cells were seeded in six T75 flasks. Cells were trypsinized 
and counted on each day, then total RNA was extracted as described [4]. Ordinate, cell number; Abscissa, time (day) after seeding. C. Expression of 
Kret'-I and $29 rp genes in HT29 cells in different growth states. Northern blot analysis was performed as described in (A). Total RNA extracted from 
HT29 cells in each growth state in (B) is electrophoresed on the corresponding lane. The results hown are representative of two independent experiments. 
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3.3. Expression of the $29 rp and Krev-1 mRNAs in HT29 
cell line and the differentiated subclone, C III 
Since S29rp mRNA seemed to be correlated with ma- 
lignant phenotypes of colon carcinoma cells, we compared 
the mRNA level with that of a tumor suppressor, K rev-1. 
Northern blot analysis was performed using total RNA 
extracted from confluent HT29 and C III cells. As shown 
in Fig. 2A, the expression of $29 rp mRNA (0.3 kb) was 
higher in HT29 cells than in C III cells. In contrast, the 
expression of K rev-1 mRNA was higher in C III cells than 
in parental HT29 cells. We also examined the expression 
of these genes in HT29 cells under different growth condi- 
tions. As shown in Fig. 2B, cells kept proliferating until 
the culture became confluent (day 5 to day 6). The expres- 
sion of $29 rp mRNA was lower in rapidly proliferating 
HT29 cells in lower cell density, while that was increased 
and reached to maximal in the confluent cells. By contrast, 
the expression of K rev-1 was the highest in rapidly prolif- 
erating HT29 cells, but was decreased in subconfluent or 
confluent cultures (Fig. 2C). Thus, $29 rp mRNA was 
upregulated in undifferentiated and growth arrested HT29 
cells, whereas the level of K rev-I mRNA was inversely 
correlated with that of $29 rp mRNA in these cells. 
3.4. Reversion assay 
In order to examine the functional correlation of $29 rp 
and K rev-1, we performed the reversion assay on a v-Ki- 
ras transformed cell line, DT [2,6]. For this, we co-trans- 
fected DT cells with the expression vectors containing an 
activated form of Krev-l(63E) and the $29 rp cDNAs, 
selected with G418 and scored the ratio of fiat to total 
colonies (Table 1). K rev-l(63E) cDNA alone induced flat 
reversion in 2.5% of the total colonies (Expt. I), while 
under the same conditions, $29 rp cDNA alone induced 
less than 1% of flat revertants (Expt. I and II). Interest- 






Fig. 3. Zinc blot assay using bacterially synthesized $29 rp (lane 1) and 
$29 rp(ms) (lane 2). Equal amounts of protein were transferred on the 
membranes and stained with (a) coomassie brilliant blue, (b) probed with 
anti $29 rp antibody, and (c) probed with a 65ZNC12, respectively. 
Relative molecular weight was indicated (kDa). 
5.2% in the co-transfectant of $29 rp and Krev-l(63E) 
(Expt. I). This apparent cooperation of $29 rp and K rev-1 
did not depend on the 5'untranslated region of Krev-1 
cDNA, since $29 rp also cooperated with K rev-l(63E) A 
(Expt. II and III). These results suggest hat flat colony 
forming activity of Krev-l(63E) was significantly en- 
hanced by $29 rp. 
3.5. Function of zinc finger-like domain 
$29 rp has a potential C2-C 2 type zinc finger motif 
(Fig. 1 arrowheads). In order to examine zinc binding 
activity of $29 rp, zinc blot assay was performed. As 
shown in Fig. 3a and b, Coomasie blue stain and anti-S29 
antibody detected the same amount of both wild-type $29 
Table 1 
Flat reversion in DT cells transfected with K rev-l(63E) and $29 rp expression vectors 
Expt. Frequency of reversion c (ratio, %) 
Vector b $29 rp S29rp (ms) 
I Vector a 2/872 (< 0.5) 7/844 (0.8) ++ 
K rev(63E) 13/512 (2.5) 24/464 (5.2) + 
8/344 (2.3) + ÷ + 
4 /1296(<0.5)  +++ 
II Vector a 0/416 (< 0.5) 5/516 (1.0) + 7/488 (1.4) + 
K rev(63E) A 30/688 (4.5) 29/391 (7.4) + N.D. 
III Vector a 0/248 ( < 0.4) N.D. N.D. 
K rev(63E) A 19/472 (4.0) 58/516 (11.2) +++ 33/496 (6.6) 
a pcEXV-I; b pRc/CMV. 
c Flat colonies/Total neo resistant colonies. 
+ P < 0 05; +÷ P < 0.01; +++ P < 0.001 compared to pRc/CMV transfectant. 
N.D., not done. 
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rp and a mutant, $29 rp(ms), which contain cysteine-to- 
alanine substitutions at the second cysteine pair. The iden- 
tical membrane was probed with 6SZnC12. Wild-type $29 
rp bound 65Zn(II), however $29 rp(ms) could not (Fig. 3c). 
These results suggest hat the C2-C 2 structure of $29 rp 
takes a zinc finger confornaation and the mutation intro- 
duced in $29 rp(ms) disruplEs the structure. 
We also examined the effect of $29 rp(ms) on the 
reversion of DT cells. As shown in Table 1, Expt. I and IF, 
$29 rp(ms) alone induced flat colonies at low frequencies. 
However, in contrast o wild-type $29 rp, $29 rp(ms) did 
not enhance flat colony formation either with K rev-l(63E) 
or with K rev-l(63E) A in DT cells (Expt. I and III). These 
results suggest hat flat colony forming activity solely with 
$29 rp does not depend on the zinc finger-like motif, 
whereas the co-operative function of $29 rp with K re~'- 
1(63E) is conferred by this motif. 
protein but not for its reversion inducing activity by itself. 
These findings raise the possibility that K rev-1 may exert 
its reversion-inducing activity through $29 rp. Several 
recent investigations have shown that Raf proteins are 
functionally located downstream of Ras proteins [22-26]. 
Ras transformation i volves the direct physical association 
between Ras and the Raf kinase using a Raf zinc finger 
domain as well as the other domain [27-29]. Our findings, 
together with these facts, may suggest hat $29 rp has a 
physical association with K rev-1 protein at the zinc finger 
domain and functions as an effector for that molecule. 
In any event, we believe that this newly recognized 
interaction between K rev-1 and $29 rp deserves further 
investigation to understand the mechanisms of both the 
transformation suppression by K rev-1 and the function of 
$29 rp in cell growth and differentiation. 
4. Discussion 
In this study, one of the genes down-regulated in a 
differentiated subclone of HT29 human colon carcinoma 
cell line was found to encode a component of small 
ribosomal subunit, $29 q). The functions of ribosomal 
proteins upon transformation are diverged. Some riboso- 
mal protein mRNAs, including P2 [12], L31 [13], S19 [4], 
L18 [14], L37 [15], ubiquitin-S27a [16], $3, $6, $8, S12 
and P0 [17] are overexpressed in colon carcinomas, while 
L19 [18] and $2 [19] are overexpressed in breast and 
squamous carcinomas, respectively. Enhancement of these 
ribosomal subunits may play some causal effects in the 
proliferation potential of neoplasia. On the other hand, 
ribosomal proteins $6 in Drosophila [20] and $25 in rat 
liver [21 ] are suggested to have tumor suppressor activity. 
We observed an interesting inverse correlation between 
the expression of $29 rp and K rev-1 mRNAs. Our obser- 
vation that K rev-1 mRNA is more abundant in the differ- 
entiated CIII cells is consistent with our notion that this 
gene probably serves as a negative growth regulator: 
K rev-1 is originally identified as a transformation suppres- 
sor gene antagonizes activated ras oncogene [1]. On the 
other hand, Krev-1 was downregulated in confluent and 
growth-arrested HT29 ceitls. This seems contradictory to 
the above notion. This, however, may be understood if we 
assume that Kree-1 and 5;29 rp cooperate with each other 
in growth suppression. Our finding that wild-type $29 rp 
induces flat reversion when overexpressed in DT cells is 
consistent with this model. Further, the inverse correlation 
of the levels of these ml~'qAs may reflect some kind of 
feed back regulation to keep the effects of this system 
constant under different conditions. 
We have demonstrated that the $29 rp can bind zinc 
and that the C2-C 2 motif is essential for binding. Judging 
from the behavior of the 5;29 rp(ms), this domain of $29 rp 
is required for its functional cooperation with the K rev-1 
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